Stockscreener 앱 받기
14.47
0.00%
0.00
전일 마감가:
$14.47
열려 있는:
$13.77
하루 거래량:
594.52K
Relative Volume:
1.10
시가총액:
$789.19M
수익:
-
순이익/손실:
-
주가수익비율:
-
EPS:
-
순현금흐름:
-
1주 성능:
+11.57%
1개월 성능:
+23.04%
6개월 성능:
-28.26%
1년 성능:
+0.00%
1일 변동 폭
$13.41
$15.30
1주일 범위
$12.69
$15.30
52주 변동 폭
$8.91
$28.09
Bicara Therapeutics Inc Stock (BCAX) Company Profile
명칭
Bicara Therapeutics Inc
전화
617-785-8308
주소
245 MAIN STREET, CAMBRIDGE
BCAX을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
BCAX
Bicara Therapeutics Inc
|
14.47 | 707.33M | 0 | 0 | 0 | 0.00 |
|
ONC
Beigene Ltd Adr
|
228.38 | 25.07B | 3.81B | -644.79M | -669.77M | -6.24 |
|
VRTX
Vertex Pharmaceuticals Inc
|
438.65 | 109.14B | 11.10B | -988.90M | -1.26B | -3.92 |
|
AKTX
Akari Therapeutics Plc Adr
|
1.27 | 36.39M | 0 | 0 | 0 | 0.00 |
|
REGN
Regeneron Pharmaceuticals Inc
|
594.32 | 56.98B | 14.09B | 4.50B | 2.96B | 39.28 |
|
VRNA
Verona Pharma Plc Adr
|
71.31 | 5.39B | 0 | -153.72M | -103.81M | -2.00 |
Bicara Therapeutics Inc Stock (BCAX) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-04-17 | 개시 | Wells Fargo | Underweight |
| 2025-02-06 | 개시 | Wedbush | Outperform |
| 2024-12-06 | 개시 | H.C. Wainwright | Buy |
| 2024-11-05 | 개시 | Rodman & Renshaw | Buy |
| 2024-10-08 | 개시 | Cantor Fitzgerald | Overweight |
| 2024-10-08 | 개시 | Morgan Stanley | Overweight |
| 2024-10-08 | 개시 | Stifel | Buy |
| 2024-10-08 | 개시 | TD Cowen | Buy |
모두보기
Bicara Therapeutics Inc 주식(BCAX)의 최신 뉴스
Bicara Therapeutics price target lowered to $41 from $44 at H.C. Wainwright - TipRanks
Bicara Therapeutics (NASDAQ:BCAX) Shares Gap Down on Analyst Downgrade - Defense World
The Manufacturers Life Insurance Company Has $508,000 Stake in Bicara Therapeutics Inc. (NASDAQ:BCAX) - Defense World
Q2 EPS Estimates for Bicara Therapeutics Lowered by Wedbush - Defense World
Pentair To Rally More Than 15%? Here Are 10 Top Analyst Forecasts For Friday - Benzinga
H.C. Wainwright cuts Bicara Therapeutics stock target to $41 - Investing.com
H.C. Wainwright cuts Bicara Therapeutics stock target to $41 By Investing.com - Investing.com India
Cautious Outlook on Bicara Therapeutics Inc. Amid Uncertain Pipeline and Market Underperformance - TipRanks
Bicara Therapeutics reports Q1 EPS (68c), consensus (40c) - TipRanks
Bicara Therapeutics (NASDAQ:BCAX) Shares Down 8.7% After Earnings Miss - Defense World
Bicara Therapeutics Reports Q1 2025 Financial Results - TipRanks
Promising Clinical Progress and Strategic Expansion Drive Buy Rating for Bicara Therapeutics - TipRanks
Promising Potential of Bicara Therapeutics’ Ficera: A Buy Rating Backed by Strong Clinical Data and Innovative Approach - TipRanks
Bicara Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Update - Bluefield Daily Telegraph
Bicara Therapeutics (NASDAQ:BCAX) Shares Gap Down – Should You Sell? - Defense World
Bicara Therapeutics Inc (NASDAQ: BCAX) Metrics That Matter Right Now - Stocksregister
Wells Fargo & Company MN Purchases New Shares in Bicara Therapeutics Inc. (NASDAQ:BCAX) - Defense World
Barclays PLC Buys 20,107 Shares of Bicara Therapeutics Inc. (NASDAQ:BCAX) - Defense World
MetLife Investment Management LLC Makes New Investment in Bicara Therapeutics Inc. (NASDAQ:BCAX) - Defense World
Invesco Ltd. Makes New Investment in Bicara Therapeutics Inc. (NASDAQ:BCAX) - Defense World
Analysts Set Bicara Therapeutics Inc. (NASDAQ:BCAX) PT at $32.43 - Defense World
A new trading data show Bicara Therapeutics Inc (BCAX) is showing positive returns. - Sete News
Legal & General Group Plc Acquires New Holdings in Bicara Therapeutics Inc. (NASDAQ:BCAX) - Defense World
Bicara Therapeutics Inc [BCAX] Shares Fall -3.43 % on Wednesday - knoxdaily.com
A closer look at Bicara Therapeutics Inc (BCAX)’s stock price trends - uspostnews.com
Wedbush Lifts Earnings Estimates for Bicara Therapeutics - Defense World
Promising Potential of Bicara Therapeutics’ Ficerafusp Alfa Drives Buy Rating Amid Encouraging Clinical Data and Growth Opportunities - TipRanks
Analysts’ Top Healthcare Picks: Bicara Therapeutics Inc. (BCAX), AstraZeneca (AZN) - The Globe and Mail
Cautious Outlook on Bicara Therapeutics Inc. Amid Efficacy and Safety Concerns for Ficerafusp - TipRanks
Promising Clinical Trial Results Boost Buy Rating for Bicara Therapeutics - TipRanks
Bicara Therapeutics Highlights Broad Potential of Ficerafusp Alfa at AACR Annual Meeting 2025 - GlobeNewswire
Riding the Waves: A Guide to Investing in BCAX Stock - investchronicle.com
JPMorgan Chase & Co. Buys 64,010 Shares of Bicara Therapeutics Inc. (NASDAQ:BCAX) - Defense World
Bicara Therapeutics (NASDAQ:BCAX) Shares Gap Down – Here’s Why - Defense World
Bicara Therapeutics Inc: Navigating Market Volatility with a 1.79 Debt-to-Equity Ratio - investchronicle.com
Bicara Therapeutics Inc (NASDAQ: BCAX) Is The Among Hot Stock Right Now - Stocksregister
Geode Capital Management LLC Acquires 418,003 Shares of Bicara Therapeutics Inc. (NASDAQ:BCAX) - Defense World
Bicara to present updated trial data at ASCO Meeting - Investing.com
Bicara to present updated trial data at ASCO Meeting By Investing.com - Investing.com South Africa
Bicara Therapeutics to Present Updated Data from Ongoing Phase 1/1b Trial of Ficerafusp alfa in 1L R/M HNSCC at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting - The Manila Times
Bicara Therapeutics to Present Updated Phase 1/1b Clinical Trial Data for Ficerafusp Alfa at ASCO 2025 - Nasdaq
Bicara Therapeutics (NASDAQ:BCAX) Research Coverage Started at Wells Fargo & Company - The AM Reporter
Bicara Stock: Innovative Precision Tumor Targeting (NASDAQ:BCAX) - Seeking Alpha
Wells Fargo & Company Initiates Coverage on Bicara Therapeutics (NASDAQ:BCAX) - Defense World
Wells Fargo Initiates Coverage of Bicara Therapeutics (BCAX) with Underweight Recommendation - MSN
Vanguard Group Inc. Acquires 1,020,528 Shares of Bicara Therapeutics Inc. (NASDAQ:BCAX) - Defense World
Bicara Therapeutics initiated with an Underweight at Wells Fargo - TipRanks
This Twin Disc Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Thursday - Benzinga
Wells Fargo Initiates Bicara Therapeutics at Underweight With $8 Price Target - marketscreener.com
Corebridge Financial Inc. Takes $167,000 Position in Bicara Therapeutics Inc. (NASDAQ:BCAX) - Defense World
HC Wainwright Issues Pessimistic Forecast for BCAX Earnings - Defense World
Bicara Therapeutics Inc (BCAX) 재무 분석
Bicara Therapeutics Inc (BCAX)에 대한 금융 데이터가 없습니다. 더 많은 정보를 위해 다른 주식을 확인해보세요.
매출
순이익
현금흐름
주당 순 이익
Bicara Therapeutics Inc 주식 (BCAX) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| Meisner Lara | Chief Legal Officer |
Mar 14 '25 |
Sale |
12.90 |
79,146 |
1,021,211 |
0 |
1.54%
7.58%
자본화:
|
볼륨(24시간):